Zilate, Joshua (2024) Development of intronless expression systems for biomanufacturing. PhD thesis, University of Sheffield.
Abstract
Biotherapeutic molecules, such as monoclonal antibodies (mAbs), represent a 
sizeable proportion of newly approved therapeutic’s available for treatment of disease. 
Reducing the production costs of these therapeutics, usually produced in massive 
quantities from Chinese Hamster Ovary (CHO) cells, remains a key focus of the 
pharmaceutical industry. The presence of introns in the expression cassettes of mAbs 
are an effective way of achieving high therapeutic protein expression levels. However, 
frequent mis-splicing events lead to the formation of aberrant protein structures, 
lowering the yield of the therapeutic protein and requiring filtration from the final 
product. This leads to increased production costs resulting in increased cost for the 
consumer and thus lowering the availability of the drug.
To counteract this problem, in this project we set out to develop expression systems 
with increased therapeutic protein yield from an intronless expression cassette. We 
demonstrate that improving the GC content of an intronless sequence improves 
protein expression through improved mRNA export via interactions with the mRNA 
export factor ALYREF. We go on to show that inclusion of RNA-binding protein (RBPs) 
recruitment motifs for SRSF1/SRSF7 and SF3b1 into the intronless sequence 
improves therapeutic protein expression, showing that mRNA processing is a good 
expression stage to target to in this process. We further demonstrate the potential for 
both GC content and RBP recruitment motifs to work in tandem to improve therapeutic 
protein expression and provide evidence that these improvements work in an industrial 
setting.
Finally, we investigate the role of the HUSH complex in mediated silencing of intronless 
expression sequences, showing that this HUSH complex may not play a key role in 
reducing protein expression levels from intronless sequences. Additionally, we show 
the potential of HNRNPU silencing as a method of improving therapeutic production, 
but further development of this system is required to alleviate certain drawbacks 
associated with HNRNPU silencing.
Metadata
| Supervisors: | Wilson, Stuart | 
|---|---|
| Awarding institution: | University of Sheffield | 
| Academic Units: | The University of Sheffield > Faculty of Science (Sheffield) The University of Sheffield > Faculty of Science (Sheffield) > Molecular Biology and Biotechnology (Sheffield) | 
| Depositing User: | Mr Joshua Zilate | 
| Date Deposited: | 25 Sep 2025 10:31 | 
| Last Modified: | 25 Sep 2025 10:31 | 
| Open Archives Initiative ID (OAI ID): | oai:etheses.whiterose.ac.uk:37507 | 
Download
Final eThesis - complete (pdf)
Filename: Zilate, Joshua, 200194570 Final.pdf
Licence: 
    
This work is licensed under a Creative Commons Attribution NonCommercial NoDerivatives 4.0 International License
Export
Statistics
        
            You do not need to contact us to get a copy of this thesis. Please use the 'Download' link(s) above to get a copy.
          
        You can contact us about this thesis. If you need to make a general enquiry, please see the Contact us page.